Ortin Global share news, announcements and annual reports
NSE: ORTINGLOBEBSE: 539287Pharmaceuticals & BiotechnologySmall Cap
ORTIN GLOBAL LIMITED · Formerly Ortin Laboratories · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2015 on BSE, Mar 2021 on NSE
Last close ₹13.35up ₹0.22 (1.68%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹13.13.
30 Oct: open ₹13.50, high ₹13.98, low ₹12.40
52-week range of traded prices to 30 Oct 2026
₹10.83Low, 4 Nov 2025₹21.30High, 9 Jun 2026
- Under NSE's graded surveillance, stage 0, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹11 Cr4,502nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 8.77
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −56.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −52.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.81
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,09680.2% delivered
Ortin Global share news and announcements
150 announcements, routine notices left out, newest first. Page 2 of 3.
Feb 2025
12 Feb · Results
12 Feb · Results
12 Feb · Board meeting
7 Feb · Board meeting
Nov 2024
13 Nov · Results
Oct 2024
Sep 2024
25 Sep · Board meeting
Aug 2024
13 Aug · Board meeting
13 Aug · Results
Jul 2024
24 Jul · Name Change
May 2024
30 May · Board meeting
30 May · Results
22 May · Board meeting
Apr 2024
29 Apr · Legal
Exchange has sought clarification from Ortin Laboratories Limited with respect to announcement dated 13-Feb-2024, regarding " Ortin Laboratories Limited has informed the Exchange regarding appointment of Directors On basis of above the Company is required to clarify following:ￂﾠ1. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority. The response of the Company is awaited.6 Apr · Legal
The exchange asked on 5 Apr 2024
Mar 2024
14 Mar · Meeting
Feb 2024
17 Feb · Results
13 Feb · Board meeting
9 Feb · Board meeting
6 Feb · Board meeting
Dec 2023
Nov 2023
14 Nov · Board meeting
14 Nov · Results
Oct 2023
10 Oct · Board meeting
Sep 2023
30 Sep · Meeting
6 Sep · Updates
Aug 2023
14 Aug · Board meeting
14 Aug · Results
4 Aug · Board meeting